Ultromics Secures Strategic Investment from the American Heart Association's Go Red for Women Venture Fund™

• Funding accelerates Ultromics' work to close one of medicine's most pervasive health-equity gaps: heart failure with preserved ejection fraction (HFpEF), a condition that affects millions of women worldwide yet often goes unrecognized
• Built and validated on diverse, outcomes-based data, Ultromics' AI turns a routine heart ultrasound into an objective diagnostic tool, helping clinicians identify early heart failure before symptoms are dismissed or missed

OXFORD, England, Dec. 17, 2025 -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced an investment from the American Heart Association's Go Red for Women Venture Fund, a fund within American Heart Association Ventures (the venture capital program of the American Heart Association). The funding accelerates Ultromics' mission to make early identification of heart failure a standard part of cardiac care, expanding access to its FDA-cleared AI platform already used in leading U.S. hospitals and reimbursed across public and private payers.